Neonatal Diabetes Mellitus (NDM) diagnosed before 6 months is a rare disease (approximate incidence of 1:100,000 live births) that reflects severe β cell dysfunction.
Two separate studies (Edghill et al., 2006b, Iafusco et al., 2002) have shown that diabetes diagnosed before 6 months of age is most likely to have a monogenic cause rather than being due to autoimmunity.
There are many different subtypes of neonatal diabetes defined by different genetic causes. Identifying the genetic causes of neonatal diabetes is not only relevant for patients, but also gives insights into which genes are needed for β cell formation and function.
Currently genetic testing finds a genetic diagnosis for over 85% of patients with neonatal diabetes. We provide genetic testing for neonatal diabetes for individuals with diabetes diagnosed before 9 months of age anywhere in the world and regardless of their current age.
NEWBIE Surveillance – Incidence of Neonatal Diabetes in the United Kingdom and Republic of Ireland
Key to improving treatment and care, reducing the impact of disease on families and NHS costs would be the ability to diagnose NDM as soon as possible, to enable treatment to be started much sooner. To achieve this early diagnosis we have developed a glucose test that can be performed on blood spots taken at day 5 of life as part of the NHS newborn blood spot screening programme.
We now need to collect data on infants with a diagnosis of NDM to determine whether screening for this condition is suitable and cost effective, and this is the rationale behind NEWBIE Surveillance – Incidence of Neonatal Diabetes in the United Kingdom and Republic of Ireland.
Details of this study including study objectives, outcome measures and inclusion/exclusion criteria can be found at https://www.diabetesgenes.org/current-research/newbie-study/
July 2023: Patients Referred from 113 Countries

